12:00 AM
Apr 18, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

Renvela sevelamer carbonate regulatory update

The Scottish Medicines Consortium recommended the use of sanofi-aventis' Renvela sevelamer carbonate for second-line management of hyperphosphatemia...

Read the full 64 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >